CN102010416A - 取代的四氢喹啉 - Google Patents

取代的四氢喹啉 Download PDF

Info

Publication number
CN102010416A
CN102010416A CN2010105171785A CN201010517178A CN102010416A CN 102010416 A CN102010416 A CN 102010416A CN 2010105171785 A CN2010105171785 A CN 2010105171785A CN 201010517178 A CN201010517178 A CN 201010517178A CN 102010416 A CN102010416 A CN 102010416A
Authority
CN
China
Prior art keywords
aryl
compound
heteroaryl
hal
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010105171785A
Other languages
English (en)
Chinese (zh)
Inventor
K·席曼
U·埃姆德
D·芬森格
C·阿门特
N·海斯
F·岑克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN102010416A publication Critical patent/CN102010416A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010105171785A 2005-06-13 2006-05-17 取代的四氢喹啉 Pending CN102010416A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005027170.7 2005-06-13
DE102005027170A DE102005027170A1 (de) 2005-06-13 2005-06-13 Substituierte Tetrahydrochinoline

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA200680021167XA Division CN101198613A (zh) 2005-06-13 2006-05-17 取代的四氢喹啉

Publications (1)

Publication Number Publication Date
CN102010416A true CN102010416A (zh) 2011-04-13

Family

ID=36699028

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200680021167XA Pending CN101198613A (zh) 2005-06-13 2006-05-17 取代的四氢喹啉
CN2010105171785A Pending CN102010416A (zh) 2005-06-13 2006-05-17 取代的四氢喹啉

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA200680021167XA Pending CN101198613A (zh) 2005-06-13 2006-05-17 取代的四氢喹啉

Country Status (15)

Country Link
US (1) US7893082B2 (enExample)
EP (1) EP1891076B1 (enExample)
JP (1) JP5180070B2 (enExample)
KR (1) KR20080030015A (enExample)
CN (2) CN101198613A (enExample)
AR (1) AR054616A1 (enExample)
AU (1) AU2006312800B2 (enExample)
BR (1) BRPI0611613A2 (enExample)
CA (1) CA2611889C (enExample)
DE (1) DE102005027170A1 (enExample)
ES (1) ES2566729T3 (enExample)
MX (1) MX2007015782A (enExample)
RU (1) RU2007147925A (enExample)
WO (1) WO2007054138A1 (enExample)
ZA (1) ZA200800365B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005027169A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
DE102007013855A1 (de) * 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
CL2008003063A1 (es) 2007-10-19 2010-01-04 Schering Corp Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
AU2008338015B2 (en) * 2007-12-18 2013-03-07 Merck Patent Gmbh Process for preparing tetrahydroquinoline derivatives
WO2019089412A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CA3201443A1 (en) 2020-12-25 2022-06-30 Toray Industries, Inc. Tetrahydroquinoline derivative and medicinal use thereof
KR20250026152A (ko) 2022-06-24 2025-02-25 도레이 카부시키가이샤 근위축성 측색경화증의 치료제 또는 예방제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946556A4 (en) * 1996-12-18 2001-07-04 Lilly Co Eli COMBINATORY METHOD FOR THE PREPARATION OF TETRAHYDROQUINOLEIN BANKS
US6288075B1 (en) * 1998-02-26 2001-09-11 Rhone-Poulenc Rorer S.A. Thiazolo[5,4,3-ij]quinolines, preparation and medicines containing the same
US7250423B2 (en) * 2001-09-24 2007-07-31 Chao-Jun Li Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers
WO2005016255A2 (en) * 2003-07-16 2005-02-24 Ligand Pharmaceuticals Incorporated Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds
EP2033959B1 (de) * 2003-12-20 2011-04-27 Merck Patent GmbH Tetrahydropyranochinolinderivate
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
MXPA06012323A (es) * 2004-04-28 2007-01-17 Takeda Pharmaceutical Derivado de quinolina fusionada y uso del mismo.
DE102005027169A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
MX2008016071A (es) * 2006-06-19 2009-01-15 Merck Patent Gmbh Formas polimorficas y proceso.

Also Published As

Publication number Publication date
CA2611889C (en) 2013-05-14
EP1891076A1 (de) 2008-02-27
KR20080030015A (ko) 2008-04-03
AU2006312800B2 (en) 2011-08-25
JP5180070B2 (ja) 2013-04-10
DE102005027170A1 (de) 2006-12-14
US7893082B2 (en) 2011-02-22
US20080194615A1 (en) 2008-08-14
WO2007054138A1 (de) 2007-05-18
ZA200800365B (en) 2009-05-27
BRPI0611613A2 (pt) 2010-09-21
AU2006312800A1 (en) 2007-05-18
CN101198613A (zh) 2008-06-11
MX2007015782A (es) 2008-02-22
ES2566729T3 (es) 2016-04-15
CA2611889A1 (en) 2007-05-18
JP2008545803A (ja) 2008-12-18
EP1891076B1 (de) 2016-01-27
RU2007147925A (ru) 2009-07-20
AR054616A1 (es) 2007-07-04

Similar Documents

Publication Publication Date Title
CN102414211B (zh) 3-([1,2,3]三唑-4-基)吡咯并[2,3-b]吡啶衍生物
CN102056926B (zh) 吡咯并吡啶基嘧啶-2-基胺衍生物
JP4954973B2 (ja) 癌を治療するためのｉｇｆ−ｒ１阻害剤としての（１ｈ−インドール−７−イル）−（ピリミジン−２−イルアミノ）メタノン誘導体および関連化合物
CN105732617B (zh) 7‑氮杂吲哚衍生物
CN103153951B (zh) 作为MetAP-2抑制剂的吡咯烷酮
CN101809001B (zh) 咪唑衍生物
JP5237555B2 (ja) ２−（ヘテロ）アリール置換テトラヒドロキノリン誘導体
EA019103B1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
JP2009535300A (ja) キナーゼ阻害剤としての新規なシクロブチル化合物
JP2008538773A (ja) キナーゼ阻害剤としての新規アザ複素環化合物
CN101326167A (zh) 用于治疗肿瘤的哒嗪酮衍生物
KR20100080836A (ko) 암 치료용 티아졸 유도체
KR20120083445A (ko) 종양 치료를 위한 술폭시드 유도체
KR20100112626A (ko) 4-(피롤로[2,3-ｃ]피리딘-3-일)피리미딘-2-일아민 유도체
CN103228657A (zh) 作为PDK1抑制剂的3-杂芳基-取代的吡咯并[2,3-b]吡啶衍生物
CN102010416A (zh) 取代的四氢喹啉
CN102666538A (zh) 吡咯并吡啶基嘧啶-2-基胺衍生物
JP5480636B2 (ja) 置換テトラヒドロキノリン類
CN101636401A (zh) 四氢喹啉衍生物及其用于治疗癌症的应用
CN101341151A (zh) 二氮杂䓬酮类
JP5121450B2 (ja) テトラヒドロキノリン
JP2010521504A (ja) 置換テトラヒドロピロロキノリン類
EP1963272A1 (de) Hydroxychinolinderivate
CN100567289C (zh) 2-(杂)芳基-取代的四氢喹啉衍生物
KR101211973B1 (ko) 2-(헤테로)-아릴-치환 테트라하이드로퀴놀린 유도체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110413